GUCY2C

GUCY2C

GUCY2C Overview

Molecule Name
Heat-stable enterotoxin receptor
Synonyms
GUCY2C,GUC2C,STAR,STA receptor,hSTAR,GC-C
Drug Development Progress
Drugs in Clinical Trials9
Approved Drugs1
Highest Development StageApproved
Target Synonym
GUC2C,Intestinal guanylate cyclase,hSTAR,EC:4.6.1.2,EC 4.6.1,GC-C,GUCY2C,Guanylate Cyclase 2C,STA Receptor,Guanylyl Cyclase C,Guanylate Cyclase 2C (Heat Stable Enterotoxin Receptor),Heat-Stable Enterotoxin Receptor,STAR,Heat Stable Enterotoxin Receptor,EC 4.6.1.2,DIAR6,MECIL,MUCIL
Background
GUCY2C (Guanylyl Cyclase C), also known as heat-stable enterotoxin receptor, is a type I transmembrane protein of the guanylate cyclase (gc) family that signal by producing cGMP. Guanylate cyclase C (GUCY2C) and its hormones guanylin and uroguanylin have recently emerged as one paracrine axis defending intestinal mucosal integrity against mutational, chemical, and inflammatory injury. GUCY2C murine CAR-T cells recognized and killed human colorectal cancer cells endogenously expressing GUCY2C. Thus, we have identified a human GUCY2C-specific CAR-T cell therapy approach that may be developed for the treatment of GUCY2C-expressing metastatic colorectal cancer.

GUCY2C Product List

Species
  • Human(14)
  • Mouse(4)
  • Cynomolgus(3)
Tag
  • His Tag(13)
  • Fc Tag(4)
  • His Tag & Avi Tag(3)
  • Fc Tag & Avi Tag(1)
Host
  • HEK293(20)
  • CHO(1)
Conjugate
  • Unconjugated(7)
  • Biotin-labeled(4)
  • FITC Labeled(3)
  • APC Labeled(2)
  • PE Labeled(2)
  • AF488 Labeled(1)
  • AF555 Labeled(1)
  • AF647 Labeled(1)
Grade
  • RUO(21)
Low Endotoxin
  • Yes(3)
  • No(18)
You Have Viewed 1-10 Of 21 Results
  • 1
  • 2
  • 3

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity

Project Cooperation

Project NameDrug TypeTherapeutic AreaIndicationStageRights Area
Anti-GCC humanized antibodyBispecific antibodyOncology/CancerSolid TumorPreclinicalGlobal
Drug Type
Bispecific antibody
Therapeutic Area
Oncology/Cancer
Indication
Solid Tumor
Stage
Preclinical
Rights Area
Global
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
anti-GUCY2C CAR T-cell therapy (Parasol Biotechnology/Anhui provincial cancer hospital)Phase 1 ClinicalHeFei Parasol Biotech Co Ltd
Colorectal Neoplasms
Details
anti-guanylyl cyclase C CAR-T cell therapy (Legend Biotech)LCAR-G08TPhase 1 ClinicalLegend Biotech Corp
Colorectal Neoplasms; Gastrointestinal Neoplasms
Details
HD-006HD006; HD-006Phase 1 ClinicalHuadao (Shanghai) Biopharma Co Ltd
Solid tumours
Details
REVO-UWD-01REVO-UWD-01; WD 01Phase 1 ClinicalWondercel Therapeutics Co Ltd
Colorectal Neoplasms
Details
IM96 CAR-T cell TherapyIM96Phase 1 ClinicalImunopharm Technology Co Ltd
Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms
Details
GCC19CARTGCC19CART; LYL273; LYL-273Phase 1 ClinicalInnovative Cellular Therapeutics Co Ltd
Colorectal Neoplasms; Rectal Neoplasms
Details
Gucy2c cart cell therapy (Innovative Cellular Therapeutics)Phase 1 ClinicalInnovative Cellular Therapeutics Co Ltd
Digestive System Neoplasms
Details
XKDCT-080XKDCT-080ClinicalThe Affiliated Hospital Of Qingdao University
Colonic Neoplasms; Solid tumours
Details
CT-080CT-080ClinicalShenzhen Celconta Life Science Co Ltd
Solid tumours
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
PlecanatideSP-304; GCRAApprovedSynergy Pharmaceuticals IncTrulanceUnited StatesConstipation; Chronic idiopathic constipationSalix Pharmaceuticals2017-01-19
Chronic idiopathic constipation; Constipation; Irritable Bowel Syndrome
Details
Customer Reviews